HK Stock Market Move | BIOCYTOGEN-B (02315) surged nearly 20% and officially entered the Hong Kong stock connect list today.

BIOCYTOGEN-B (02315) surged nearly 20% in early trading, as of the time of writing, it has risen by 19.51%, at 34.3 Hong Kong dollars, with a turnover of 22.7351 million Hong Kong dollars. On the news front, the Shanghai and Shenzhen Stock Exchanges announced that due to the end of the stabilisation period for BIOCYTOGEN-B in the Hong Kong market and the corresponding A-share listing for more than 10 trading days, according to relevant regulations, the list of stocks under the Stock Connect program will be adjusted and will take effect from December 24, 2025, with BeiAoSaiTu included. Guotai Haitong previously pointed out that BeiAoSaiTu is a leading domestic preclinical CRO and life technology company, with a globally leading gene editing technology platform and a rich resource of model mice. It is vigorously developing its antibody development business through the "Thousand Mice, Ten Thousand Antibodies" program, with strong growth potential in its overseas business.